The advent of potent combination antiretroviral therapy hasled to a profound decrease in the rate of illness related tothe acquired immunodeficiency syndrome (AIDS) and has significantlyimproved survival among patients living with human immunodeficiencyvirus (HIV) infection in the developed world. A concerted effortis now under way to extend these benefits to infected personsliving in resource-poor countries. The success of antiretroviraltherapy is tempered, however, by the occurrence of drug-relatedtoxic effects in many patients. Improvements in AIDS-free survivalmean that many people face the prospect of decades of therapy,and concern about long-term toxic effects . . . [Full Text of this Article]
Source Information
From the Section of Retroviral Therapeutics, Division of Infectious Diseases, Brigham and Women's Hospital, and the Division of AIDS, Harvard Medical School — both in Boston (D.R.K.); and the Division of Infectious Diseases, Center for Clinical AIDS Research and Education, University of California, Los Angeles, Los Angeles (J.C.).
This article has been cited by other articles:
Kreisberg, R. A., Oberman, A.
(2003). Medical Management of Hyperlipidemia/Dyslipidemia. J. Clin. Endocrinol. Metab.
88: 2445-2461
[Full Text]
